Work

Results of the safety run-in of gedatolisib plus talazoparib in advanced triple negative or BRCA 1/2 positive HER2 negative breast cancer.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.e13075

Authors: Sneha Deepak Phadke, Menggang Yu, Kathy Miller, Ami N. Shah, Oana Cristina Danciu, Kari Braun Wisinski

Institutions: University of Iowa, University of Wisconsin–Madison, Indiana University Health, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Northwestern University, University of Illinois Chicago, University of Wisconsin Carbone Cancer Center

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Pfizer

OpenAlex ID: W4281617847

Cites:

Cited by: 4

Related to: 10